Addex Therapeutics Ltd. Sponsored ADR (NASDAQ:ADXN) Sees Large Drop in Short Interest

Addex Therapeutics Ltd. Sponsored ADR (NASDAQ:ADXN) was the recipient of a significant decline in short interest during the month of August. As of August 31st, there was short interest totaling 4,133 shares, a decline of 41.6% from the August 15th total of 7,083 shares. Currently, 0.4% of the company’s stock are short sold. Based on an average daily volume of 656,208 shares, the days-to-cover ratio is presently 0.0 days.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Addex Therapeutics in a report on Monday, July 6th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Addex Therapeutics presently has an average rating of “Sell”.

Addex Therapeutics Stock Performance

Shares of ADXN opened at $3.24 on Wednesday. The stock has a market capitalization of $3.99 million, a P/E ratio of -0.55 and a beta of 1.47. Addex Therapeutics has a 1 year low of $3.10 and a 1 year high of $11.97. The company’s fifty day moving average is $5.03 and its two-hundred day moving average is $6.03.

About Addex Therapeutics

Addex Therapeutics SA is a clinical-stage biopharmaceutical company specializing in the discovery and development of small-molecule allosteric modulators for central nervous system disorders. Founded in 1999 and headquartered in Geneva, Switzerland, with a U.S. research presence in Cambridge, Massachusetts, the company focuses on targeting metabotropic glutamate (mGlu) receptors and GABAB receptors to address unmet medical needs in neurology and psychiatry.

The company’s lead candidate, dipraglurant (ADX48621), is an mGlu5 negative allosteric modulator in clinical development for levodopa-induced dyskinesia in Parkinson’s disease.